Dedicated to improving the outcome for heart failure patients with Central Sleep Apnea.

The remedē® System – an innovative implantable stimulation therapy solution.

Central Sleep Apnea and Heart Failure

Heart failure patients have a 1 in 3 chance of having Central Sleep Apnea. Central Sleep Apnea (CSA) is often silent, with symptoms similar to heart failure such as fatigue, poor energy, and nocturia. CSA worsens heart failure progression, decreases quality of life, and increases mortality rates. Treatment of CSA has the potential to improve heart failure symptoms and outcomes.




How the remedē® System Works

The remedē® System is designed to improve central sleep apnea by restoring natural breathing during sleep… one breath at a time.

Read More

1 in 3 people with heart failure have Central Sleep Apnea and stop breathing during the night. Talk to your doctor about the remedē® System clinical study to see if you qualify.
Send us an email at info@respicardia.com or read about our clinical study at www.clinicaltrials.gov.


Respicardia®, Inc.
12400 Whitewater Dr., Suite 150
Minnetonka, MN 55343 USA
See Map
Phone: +1-952-540-4470
E-mail: info@respicardia.com
©2018 Respicardia®, Inc. The remedē® System has received FDA and CE Mark approvals. See Patents